Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | AURKA | O14965 | 3/20 | 0.50 |
| ▸ | GSK3B | P49841 | 3/20 | 0.50 |
| ▸ | KDR | P35968 | 3/20 | 0.50 |
| ▸ | IGF1R | P08069 | 2/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.50 |
| ▸ | CDK1 | P06493 | 2/20 | 0.50 |
| ▸ | LYN | P07948 | 2/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.50 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.50 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.50 |
| ▸ | MARK3 | P27448 | 2/20 | 0.50 |
| ▸ | BLK | P51451 | 2/20 | 0.50 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.50 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.50 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 0.50 |
| ▸ | PLK3 | Q9H4B4 | 2/20 | 0.50 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.50 |
| ▸ | GSK3A | P49840 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6486739 | 0.88 | MKNK1 (0.45) | CDK2MAPK1AURKAGSK3BKDR | |
| Quinoline SCHEMBL28107595 | 0.85 | ALDH1A1 (0.53) | CDK2MAPK1AURKAGSK3BKDR | |
| SCHEMBL6323476 | 0.81 | MEN1 (0.47) | CDK2KDRCDK1NPC1RAB9A | |
| SCHEMBL27770482 | 0.80 | MAP3K5 (0.60) | CDK2MAPK1AURKAGSK3BKDR | |
| SCHEMBL31381352 | 0.80 | MAP3K5 (0.60) | CDK2MAPK1AURKAGSK3BKDR | |
| SCHEMBL167891 | 0.80 | MAP3K5 (0.60) | CDK2MAPK1AURKAGSK3BKDR | |
| Benzene SCHEMBL28188863 | 0.80 | MAP3K5 (0.60) | CDK2MAPK1AURKAGSK3BKDR | |
| SCHEMBL4573935 | 0.79 | MAP3K5 (0.58) | CDK2MAPK1AURKAGSK3BKDR | |
| Hydrochloric Acid SCHEMBL8807679 | 0.79 | MAP3K5 (0.58) | CDK2MAPK1AURKAGSK3BKDR | |
| SCHEMBL12120895 | 0.77 | JAK2 (0.51) | CDK2MAPK1AURKAGSK3BKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786799-B1 | NOVEL PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | NATCO PHARMA LTD (IN) | 2012-07-04 | — | — | EP | claimed |
| EP-1730124-A4 | CERTAIN TRIAZOLE-BASED COMPOUNDS, COMPOSITIONS, AND USES THEREOF | AMPHORA DISCOVERY CORP (US) | 2009-04-01 | — | — | EP | claimed |
| EP-1730124-A1 | CERTAIN TRIAZOLE-BASED COMPOUNDS, COMPOSITIONS, AND USES THEREOF | Amphora Discovery Corporation (US) | 2006-12-13 | — | — | EP | claimed |
| US-20050288347-A1 | Certain triazole-based compounds, compositions, and uses thereof | AGRIUS GROUP, LLC. | 2005-12-29 | — | — | US | claimed |
| WO-2005097758-A1 | CERTAIN TRIAZOLE-BASED COMPOUNDS, COMPOSITIONS, AND USES THEREOF | AMPHORA DISCOVERY CORPORATION (US) | 2005-10-20 | — | — | WO | claimed |
| EP-1730124-A4 | CERTAIN TRIAZOLE-BASED COMPOUNDS, COMPOSITIONS, AND USES THEREOF | AMPHORA DISCOVERY CORP (US) | 2009-04-01 | — | — | EP | disclosed |
| EP-1730124-A1 | CERTAIN TRIAZOLE-BASED COMPOUNDS, COMPOSITIONS, AND USES THEREOF | Amphora Discovery Corporation (US) | 2006-12-13 | — | — | EP | disclosed |
| US-20050288347-A1 | Certain triazole-based compounds, compositions, and uses thereof | AGRIUS GROUP, LLC. | 2005-12-29 | — | — | US | disclosed |
| WO-2005097758-A1 | CERTAIN TRIAZOLE-BASED COMPOUNDS, COMPOSITIONS, AND USES THEREOF | AMPHORA DISCOVERY CORPORATION (US) | 2005-10-20 | — | — | WO | disclosed |
| WO-2003020698-A2 | PROTEIN TYROSINE KINASE INHIBITORS | PROCHON BIOTECH LTD. (IL) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288347-A1 | Certain triazole-based compounds, compositions, and uses thereof | ABCG2, ATP5ME, DNTT | CDK2 1610/4885MAPK1 4613/4885AURKA 1447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.